Injecting hope : can gene therapy financing be the next big opportunity for insurers?

<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<rdf:Description>
<dc:creator>Rao, Anand S.</dc:creator>
<dc:date>2016-04-01</dc:date>
<dc:description xml:lang="es">Sumario: Recent developments have brought the ease and precisión of cut-and-paste technology to gene editing. The developments have raised issues of particular interest to insurers, who are well situated to offer protection or financing for genetic diseases or disorders because they are uniqueley able to assess and Price related risks</dc:description>
<dc:identifier>https://documentacion.fundacionmapfre.org/documentacion/publico/es/bib/156243.do</dc:identifier>
<dc:language>eng</dc:language>
<dc:rights xml:lang="es">InC - http://rightsstatements.org/vocab/InC/1.0/</dc:rights>
<dc:subject xml:lang="es">Seguro de personas</dc:subject>
<dc:subject xml:lang="es">Genética</dc:subject>
<dc:subject xml:lang="es">Seguro de salud</dc:subject>
<dc:subject xml:lang="es">Coberturas</dc:subject>
<dc:subject xml:lang="es">Medicina del seguro</dc:subject>
<dc:type xml:lang="es">Artículos y capítulos</dc:type>
<dc:title xml:lang="es">Injecting hope : can gene therapy financing be the next big opportunity for insurers?</dc:title>
<dc:relation xml:lang="es">En: Best's Review. - New Jersey : A.M. Best Company, 1976- = ISSN 1527-5914. - 04/04/2016 Volumen 116 Número 12 - abril 2016 , p. 24-26</dc:relation>
</rdf:Description>
</rdf:RDF>